Financials

	2022	2023
Net sales	5.41Cr 4.84Cr 4.51Cr 4.1Cr 7.72Cr 523.62Cr 7.78Cr 54Cr 21Cr 266.3Cr 20Cr 20Cr 856.07Cr	8.08Cr 7.22Cr 6.73Cr 6.11Cr 12Cr 781.18Cr 12Cr 81Cr 32Cr 397.28Cr 30Cr 30Cr 1.28TCr
Net income	-1.81Cr -1.62Cr -1.51Cr -1.37Cr -2.58Cr -175.16Cr -2.6Cr -18Cr -7.09Cr -89Cr -6.8Cr -6.65Cr -286.37Cr	-2.01Cr -1.8Cr -1.68Cr -1.52Cr -2.87Cr -194.75Cr -2.89Cr -20Cr -7.88Cr -99Cr -7.56Cr -7.39Cr -318.4Cr
Net Debt	4.21Cr 3.76Cr 3.51Cr 3.19Cr 6Cr 407.16Cr 6.05Cr 42Cr 16Cr 207.07Cr 16Cr 15Cr 665.67Cr	5.53Cr 4.94Cr 4.61Cr 4.19Cr 7.89Cr 535.34Cr 7.95Cr 55Cr 22Cr 272.26Cr 21Cr 20Cr 875.24Cr

Projected Income Statement - Annual - Alimera Sciences, Inc.

* Estimated data More financial data

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company. The Company is focused on helping patients, physicians and partners concerned with retinal health and maintaining better vision longer.

Employees

157

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq 01:30:00 14/09/2024 am IST			5-day change	1st Jan Change
5.540 ^USD	-0.18%		-.--%	-

16/24/16	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/24/16	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI

Market Cap	30Cr 27Cr 25Cr 23Cr 43Cr 2.91TCr 43Cr 301.81Cr 117.91Cr 1.48TCr 113.11Cr 110.66Cr 4.76TCr	P/E 2022	-1.05x	P/E 2023	-5.16x
Enterprise Value	36Cr 32Cr 30Cr 27Cr 51Cr 3.45TCr 51Cr 357.25Cr 139.57Cr 1.75TCr 133.89Cr 130.99Cr 5.64TCr	EV / Sales 2022	1.13x	EV / Sales 2023	3.49x
Free-Float	94.65%	Yield 2022 *	-	Yield 2023	-

16/24/16	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/24/16	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI
16/24/16	ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.	CI
11/24/11	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues	MT
11/24/11	ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week	MT
11/24/11	Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close	MT
10/24/10	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from S&P TMI Index	CI
06/24/06	Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
17/24/17	Processa Pharmaceuticals Appoints Russell Skibsted as CFO	MT
01/24/01	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Comp Value Index	CI
01/24/01	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Completeness Index	CI
01/24/01	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 2000 Index	CI
01/24/01	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 3000E Index	CI

25/24/25	Maxim Downgrades Alimera Sciences to Hold From Buy	MT
25/24/25	Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8	MT
25/24/25	Craig-Hallum Downgrades Alimera Sciences to Hold From Buy, Price Target is $5.50	MT
25/24/25	HC Wainwright Downgrades Alimera Sciences to Neutral From Buy, Price Target is $6	MT
25/24/25	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT

Alimera Sciences, Inc. Share Price

Stocks

ALIM

US0162592028

Pharmaceuticals

Valuation: Alimera Sciences, Inc.

Latest news: Alimera Sciences, Inc.

Analysts' recommendations: Alimera Sciences, Inc.

Press Releases: Alimera Sciences, Inc.

News in other languages: Alimera Sciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Alimera Sciences, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

16/24/16	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
11/24/11	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
11/24/11	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	AQ
10/24/10	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
10/24/10	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU

Manager	Title	Age	Since
Elliot Maltz DFI	Director of Finance/CFO	41	02/01/2024
Jason Werner COO	Chief Operating Officer	48	02/10/2023
Laura Cegala HRO	Human Resources Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/09/24	Margaret Pax	Issuer sale	Director	36,713	0.0675%
16/09/24	Velan Capital Investment Management LP	Issuer sale	Company	1,44,08,533	26.4940%
16/09/24	David Holland	Issuer sale	Chief Marketing Officer & SVP	12,32,852	2.2669%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALIMERA SCIENCES, INC.	-0.18%	-.--%	-.--%	+69.42%	29Cr
ELI LILLY AND COMPANY	+2.45%	+2.64%	+40.77%	+107.71%	1,03200Cr
JOHNSON & JOHNSON	+1.49%	-2.41%	+36.78%	+62.96%	61TCr
ABBVIE INC.	+1.55%	+3.86%	+16.69%	+82.21%	47TCr
MERCK & CO., INC.	+0.28%	-1.76%	+62.94%	+36.60%	35TCr
ROCHE HOLDING AG	+2.92%	+3.12%	+24.78%	+43.51%	34TCr
NOVARTIS AG	+2.42%	+0.05%	+14.13%	+36.19%	27TCr
ASTRAZENECA PLC	+1.86%	-0.81%	-4.69%	+12.20%	25TCr
AMGEN INC.	+2.42%	-2.35%	+39.28%	+51.59%	22TCr
GILEAD SCIENCES, INC.	+1.63%	-1.49%	+25.73%	+95.61%	18TCr
Average	+1.46%	-3.05%	+25.64%	+59.80%	37.15TCr
Weighted average by Cap.	+1.76%	-3.18%	+31.95%	+69.19%

3 years	2.61	5.65
5 years	1.3	7.92
10 years	0	25.8